Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial (Q39119506)
Jump to navigation
Jump to search
scientific article published on 5 December 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial |
scientific article published on 5 December 2016 |
Statements
1 reference
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial (English)
1 reference
Nicholas J Vogelzang
Christopher Parker
Lin Zhan
Paul Cislo
Jonathan Reuning-Scherer
Sten Nilsson
Joe M O'Sullivan
5 December 2016
1 reference